Pharmacoeconomic analysis of alogliptin use in the treatment of type 2 diabetes

Abstract

Aim of the study: Determine the validity of alogliptin choice in comparison with other DPP-4 inhibitors, available in Russia (saxagliptin, linagliptin, vildagliptin, sitagliptin) for add-on treatment in patients with inadequate glycemic control on metformin monotherapy, basing on pharmacoeconomic analysis Methodology. Retrospective modeling was performed according to standard pharmacoeconomic methods: cost-minimization analysis, cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and sensitivity analyzes. To predict the long-term impact of the compared therapies on CUA results, a Markov model with 10-year simulation horizon has been used. Results. CEA results showed that lowering HbA1C level by 1% using alogliptin was less expensive than using other agents of the group (sitagliptin, vildagliptin, saxagliptin, linagliptin). The calculated cost per QALY gained for alogliptin therapy was 27 150 rubles, which made the use of alogliptin cost-effective. Conclusions. Alogliptin is a cost-effective alternative in comparison with any other DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin) for adding to unsuccessful metformin monotherapy.

Keywords

• сахарный диабет 2-го типа
• ингибиторы дпп-4
• анализ эффективности затрат
• анализ полезности затрат
• алоглиптин